ID

31971

Beskrivning

Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use; ODM derived from: https://clinicaltrials.gov/show/NCT01083160

Länk

https://clinicaltrials.gov/show/NCT01083160

Nyckelord

Versioner (1)
  1. 2018-10-09 2018-10-09 -
Rättsinnehavare

See clinicaltrials.gov

Uppladdad den

9 oktober 2018

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Rheumatoid Arthritis NCT01083160

Engelsk

Eligibility Rheumatoid Arthritis NCT01083160

1 Formulär  
Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients ≥18 and <75 years of age that meet the american college of rheumatology (acr) criteria for ra.
Beskrivning

Age | ACR Criteria Fulfill Rheumatoid Arthritis

Datatyp

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2,1]
C3273747
UMLS CUI [2,2]
C1550543
UMLS CUI [2,3]
C0003873
patients with active ra defined as:
Beskrivning

Rheumatoid Arthritis

Datatyp

boolean

Alias
UMLS CUI [1]
C0003873
1. ≥3 tender joints and ≥3 swollen joints, or
Beskrivning

Tender joint count | Swollen joint count

Datatyp

boolean

Alias
UMLS CUI [1]
C0451530
UMLS CUI [2]
C0451521
2. das 28 score >3.1
Beskrivning

Disease activity score DAS28

Datatyp

boolean

Alias
UMLS CUI [1]
C4481729
patients who are discontinuing treatment with either infliximab or etanercept due to:
Beskrivning

Infliximab Discontinued | Etanercept Discontinued

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0666743
UMLS CUI [1,2]
C1444662
UMLS CUI [2,1]
C0717758
UMLS CUI [2,2]
C1444662
1. lack of efficacy, or
Beskrivning

Lack of Efficacy

Datatyp

boolean

Alias
UMLS CUI [1]
C0235828
2. incomplete response.
Beskrivning

Response Incomplete

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1704632
UMLS CUI [1,2]
C0205257
patients that, in the opinion of the physician could result beneficiated with the locally approved treatment scheme of adalimumab
Beskrivning

adalimumab | Therapeutic procedure Patient benefit

Datatyp

boolean

Alias
UMLS CUI [1]
C1122087
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0030705
UMLS CUI [2,3]
C0814225
those patients who switch from infliximab or etanercept to adalimumab has been done in the last 60 days could be included in the study.
Beskrivning

Infliximab | Etanercept | Therapy change | Adalimumab

Datatyp

boolean

Alias
UMLS CUI [1]
C0666743
UMLS CUI [2]
C0717758
UMLS CUI [3]
C3665894
UMLS CUI [4]
C1122087
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
the following patients will not be included in the study:
Beskrivning

Patients Excluded

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C0332196
patients who have active infections.
Beskrivning

Communicable Diseases

Datatyp

boolean

Alias
UMLS CUI [1]
C0009450
patients with latent tb. for this protocol, evidence of latent tb infection is defined as an induration (not erythema) of 5 mm or greater, 48-72 hrs after placement. any suggested data on the clinical history or chest x-ray.
Beskrivning

Latent Tuberculosis | Induration Thickness | Data Suggestive Medical History | Data Suggestive Chest X-ray

Datatyp

boolean

Alias
UMLS CUI [1]
C1609538
UMLS CUI [2,1]
C0332534
UMLS CUI [2,2]
C1280412
UMLS CUI [3,1]
C1511726
UMLS CUI [3,2]
C0332299
UMLS CUI [3,3]
C0262926
UMLS CUI [4,1]
C1511726
UMLS CUI [4,2]
C0332299
UMLS CUI [4,3]
C0039985
patients participating into another study or clinical trial
Beskrivning

Study Subject Participation Status

Datatyp

boolean

Alias
UMLS CUI [1]
C2348568
any condition that according to the criteria of the participating physician represents an obstacle for study conduct and/or represents a potential unacceptable risk for patients.
Beskrivning

Condition Interferes with Completion of clinical trial | Condition Study Subject Participation Status At risk

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C2732579
UMLS CUI [2,1]
C0348080
UMLS CUI [2,2]
C2348568
UMLS CUI [2,3]
C1444641
Tillbaka till toppen

Similar models

Eligibility Rheumatoid Arthritis NCT01083160

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
Age | ACR Criteria Fulfill Rheumatoid Arthritis
Item
patients ≥18 and <75 years of age that meet the american college of rheumatology (acr) criteria for ra.
boolean
C0001779 (UMLS CUI [1])
C3273747 (UMLS CUI [2,1])
C1550543 (UMLS CUI [2,2])
C0003873 (UMLS CUI [2,3])
Rheumatoid Arthritis
Item
patients with active ra defined as:
boolean
C0003873 (UMLS CUI [1])
Tender joint count | Swollen joint count
Item
1. ≥3 tender joints and ≥3 swollen joints, or
boolean
C0451530 (UMLS CUI [1])
C0451521 (UMLS CUI [2])
Disease activity score DAS28
Item
2. das 28 score >3.1
boolean
C4481729 (UMLS CUI [1])
Infliximab Discontinued | Etanercept Discontinued
Item
patients who are discontinuing treatment with either infliximab or etanercept due to:
boolean
C0666743 (UMLS CUI [1,1])
C1444662 (UMLS CUI [1,2])
C0717758 (UMLS CUI [2,1])
C1444662 (UMLS CUI [2,2])
Lack of Efficacy
Item
1. lack of efficacy, or
boolean
C0235828 (UMLS CUI [1])
Response Incomplete
Item
2. incomplete response.
boolean
C1704632 (UMLS CUI [1,1])
C0205257 (UMLS CUI [1,2])
adalimumab | Therapeutic procedure Patient benefit
Item
patients that, in the opinion of the physician could result beneficiated with the locally approved treatment scheme of adalimumab
boolean
C1122087 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C0030705 (UMLS CUI [2,2])
C0814225 (UMLS CUI [2,3])
Infliximab | Etanercept | Therapy change | Adalimumab
Item
those patients who switch from infliximab or etanercept to adalimumab has been done in the last 60 days could be included in the study.
boolean
C0666743 (UMLS CUI [1])
C0717758 (UMLS CUI [2])
C3665894 (UMLS CUI [3])
C1122087 (UMLS CUI [4])
Item Group
C0680251 (UMLS CUI)
Patients Excluded
Item
the following patients will not be included in the study:
boolean
C0030705 (UMLS CUI [1,1])
C0332196 (UMLS CUI [1,2])
Communicable Diseases
Item
patients who have active infections.
boolean
C0009450 (UMLS CUI [1])
Latent Tuberculosis | Induration Thickness | Data Suggestive Medical History | Data Suggestive Chest X-ray
Item
patients with latent tb. for this protocol, evidence of latent tb infection is defined as an induration (not erythema) of 5 mm or greater, 48-72 hrs after placement. any suggested data on the clinical history or chest x-ray.
boolean
C1609538 (UMLS CUI [1])
C0332534 (UMLS CUI [2,1])
C1280412 (UMLS CUI [2,2])
C1511726 (UMLS CUI [3,1])
C0332299 (UMLS CUI [3,2])
C0262926 (UMLS CUI [3,3])
C1511726 (UMLS CUI [4,1])
C0332299 (UMLS CUI [4,2])
C0039985 (UMLS CUI [4,3])
Study Subject Participation Status
Item
patients participating into another study or clinical trial
boolean
C2348568 (UMLS CUI [1])
Condition Interferes with Completion of clinical trial | Condition Study Subject Participation Status At risk
Item
any condition that according to the criteria of the participating physician represents an obstacle for study conduct and/or represents a potential unacceptable risk for patients.
boolean
C0348080 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C2732579 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C2348568 (UMLS CUI [2,2])
C1444641 (UMLS CUI [2,3])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial